Expert: House Stem Cell Questions Are ‘Spot On,’ FDA Must Do More

A cell biologist praised House Energy & Commerce Committee leaders for suggesting FDA needs to step up its oversight of stem cell products amidst a surge of lawsuits and warning letters sent to violative manufacturers and clinics. “I tend to agree with the House members who sent this letter,” Paul Knoepfler, a professor in the cell biology and human anatomy department at University of California Davis School of Medicine, told Inside Health Policy . “While the FDA has done relatively...